Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Pfizer pledges $100M to new Antimicrobial Resistance Action Fund » 15:23
07/09/20
07/09
15:23
07/09/20
15:23
PFE

Pfizer

$33.57 /

-0.19 (-0.56%)

, AMGN

Amgen

$252.34 /

+0.74 (+0.29%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, LLY

Eli Lilly

$166.59 /

-2.52 (-1.49%)

, GSK

GlaxoSmithKline

$40.37 /

-0.35 (-0.86%)

, MRK

Merck

$76.99 /

-0.88 (-1.13%)

, MKGAY

Merck KGaA

$0.00 /

+ (+0.00%)

, TEVA

Teva

$11.60 /

+0.21 (+1.84%)

, TAK

Takeda Pharmaceutical

$17.36 /

-0.135 (-0.77%)

, NVO

Novo Nordisk

$65.63 /

-0.23 (-0.35%)

, JNJ

Johnson & Johnson

$143.03 /

-0.21 (-0.15%)

, NVS

Novartis

$87.53 /

-0.585 (-0.66%)

Pfizer (PFE) announced…

Pfizer (PFE) announced earlier it has pledged $100M to the new Antimicrobial Resistance, or "AMR," Action Fund, which launched today, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections. "The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies that aims to bring 2-4 new antibiotics to patients by 2030 through collaboration between pharmaceutical companies, philanthropies, development banks, and multilateral organizations to re-invigorate and accelerate antibiotic development," the company stated. "As the COVID-19 pandemic has shown, we must invest in the development of medicines now so that we are prepared to help prevent the next public health crisis," added Pfizer Chairman and CEO Albert Bourla. Other investors in the AMR Action Fund include Amgen (AMGN), Bayer (BAYRY), Roche (RHHBY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Merck (MRK), Merck KGaA (MKGAY), Teva (TEVA), Takeda Pharmaceutical (TAK), Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Novartis (NVS). Reference Link

ShowHide Related Items >><<
TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
AMGN Amgen
$252.34 /

+0.74 (+0.29%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

10:13 Today Morgan Stanley
Eli Lilly won't publish Phase 1 COVID antibody data, says Morgan Stanley
06/29/20 Mizuho
Eli Lilly price target raised to $164 from $155 at Mizuho
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
MRK Merck
$76.99 /

-0.88 (-1.13%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

05/15/20 Nord/LB
Merck KGaA downgraded to Hold from Buy at Nord/LB
03/06/20 UBS
UBS backs Neutral on Merck KGaA after Q4 results
12/02/19 Goldman Sachs
Merck KGaA reinstated with a Sell at Goldman Sachs
10/04/19 Loop Capital
Entegris price target raised to $51 from $47 at Loop Capital
TEVA Teva
$11.60 /

+0.21 (+1.84%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$87.53 /

-0.585 (-0.66%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

Upgrade
Fly Intel: Top five analyst upgrades » 10:11
07/09/20
07/09
10:11
07/09/20
10:11
REGN

Regeneron

$652.00 /

+12.31 (+1.92%)

, CSCO

Cisco

$46.71 /

+0.89 (+1.94%)

, BDX

Becton Dickinson

$257.10 /

+4.45 (+1.76%)

, SIX

Six Flags

$19.38 /

-0.12 (-0.62%)

, STZ

Constellation Brands

$184.75 /

+1.025 (+0.56%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Regeneron (REGN) upgraded to Buy from Hold at SunTrust with analyst Robyn Karnauskas citing her "deep dive" analysis in the company's pipeline and conversations with its management in modeling additional revenue build with credit to its Libtayo, Dupi, fasinumab and oncology pipeline products. 2. Cisco (CSCO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Meta Marshall saying while cognizant that Cisco's revenue will be challenged in the near to medium term from macro headwinds, the stock's multiple discount to the S&P is at 10-year highs despite the company's durable earnings growth. 3. Becton Dickinson (BDX) upgraded to Overweight from Equal Weight at Barclays with analyst Kristen Stewart saying the shares have lagged peers year-to-date, which reflects Alaris pump challenges, revision in guidance, and the market's "evolved thinking" around the company's growth outlook. 4. Six Flags (SIX) upgraded to Buy from Neutral at Janney Montgomery Scott with analyst Tyler Batory saying he sees the current valuation as attractive and prefers the company's park diversity and exposure to some of the largest market by population in the U.S. 5. Constellation Brands (STZ) upgraded to Buy from Hold at Argus with analyst John Staszak saying the company should emerge from the pandemic in a "position of strength." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
STZ Constellation Brands
$184.75 /

+1.025 (+0.56%)

SIX Six Flags
$19.38 /

-0.12 (-0.62%)

REGN Regeneron
$652.00 /

+12.31 (+1.92%)

CSCO Cisco
$46.71 /

+0.89 (+1.94%)

BDX Becton Dickinson
$257.10 /

+4.45 (+1.76%)

REGN Regeneron
$652.00 /

+12.31 (+1.92%)

07/08/20 SunTrust
Regeneron upgraded to Buy at SunTrust on Eylea resilience and pipeline
07/08/20 SunTrust
Regeneron upgraded to Buy from Hold at SunTrust
07/08/20 Canaccord
Regeneron price target raised to $700 from $660 at Canaccord
07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
CSCO Cisco
$46.71 /

+0.89 (+1.94%)

08:39 Today Morgan Stanley
Morgan Stanley upgrades Cisco to Overweight with discount to S&P at 10-year high
05:24 Today Morgan Stanley
Cisco upgraded to Overweight from Equal Weight at Morgan Stanley
07/02/20 JPMorgan
JPMorgan sees attractive opportunities in India for Cisco, Ciena
06/16/20
Fly Intel: Top five analyst upgrades
BDX Becton Dickinson
$257.10 /

+4.45 (+1.76%)

06:26 Today Barclays
Barclays upgrades Becton Dickinson to Overweight on 'window of opportunity'
04:47 Today Barclays
Becton Dickinson upgraded to Overweight from Equal Weight at Barclays
07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
07/02/20 Wells Fargo
Becton rapid antigen COVID test may be available very soon, says Wells Fargo
SIX Six Flags
$19.38 /

-0.12 (-0.62%)

06:56 Today Janney Montgomery Scott
Janney Montgomery Scott upgrades Six Flags to Buy in theme park preference shift
06:11 Today Janney Montgomery Scott
Six Flags upgraded to Buy from Neutral at Janney Montgomery Scott
06/15/20 B. Riley FBR
B. Riley FBR upgrades Six Flags ahead of China development plans
06/15/20 B. Riley FBR
Six Flags upgraded to Buy from Neutral at B. Riley FBR
STZ Constellation Brands
$184.75 /

+1.025 (+0.56%)

07:17 Today Argus
Constellation Brands upgraded to Buy from Hold at Argus
07:10 Today Argus
Constellation Brands upgraded to Buy from Hold at Argus
07/06/20 MKM Partners
Constellation Brands price target raised to $151 from $147 at MKM Partners
07/02/20 JPMorgan
Constellation Brands price target raised to $227 from $200 at JPMorgan
STZ Constellation Brands
$184.75 /

+1.025 (+0.56%)

SIX Six Flags
$19.38 /

-0.12 (-0.62%)

REGN Regeneron
$652.00 /

+12.31 (+1.92%)

CSCO Cisco
$46.71 /

+0.89 (+1.94%)

BDX Becton Dickinson
$257.10 /

+4.45 (+1.76%)

  • 27
    May
  • 21
    May
STZ Constellation Brands
$184.75 /

+1.025 (+0.56%)

SIX Six Flags
$19.38 /

-0.12 (-0.62%)

REGN Regeneron
$652.00 /

+12.31 (+1.92%)

CSCO Cisco
$46.71 /

+0.89 (+1.94%)

STZ Constellation Brands
$184.75 /

+1.025 (+0.56%)

SIX Six Flags
$19.38 /

-0.12 (-0.62%)

REGN Regeneron
$652.00 /

+12.31 (+1.92%)

CSCO Cisco
$46.71 /

+0.89 (+1.94%)

BDX Becton Dickinson
$257.10 /

+4.45 (+1.76%)

STZ Constellation Brands
$184.75 /

+1.025 (+0.56%)

SIX Six Flags
$19.38 /

-0.12 (-0.62%)

REGN Regeneron
$652.00 /

+12.31 (+1.92%)

CSCO Cisco
$46.71 /

+0.89 (+1.94%)

Hot Stocks
Abeona Therapeutics appoints Michael Amoroso as CCO » 07:36
07/09/20
07/09
07:36
07/09/20
07:36
ABEO

Abeona Therapeutics

$3.42 /

+0.025 (+0.74%)

, GILD

Gilead

$75.63 /

-0.84 (-1.10%)

Abeona Therapeutics…

Abeona Therapeutics (ABEO) announced the appointment of Michael Amoroso as senior VP and chief commercial officer, or CCO, effective immediately. Amoroso brings to Abeona over 20 years of product commercialization experience in the biotechnology and pharmaceutical industries, most recently as senior VP and head of worldwide commercial, cell therapy at Kite, a Gilead company (GILD). Amoroso will have overall responsibility for building the company's commercial organization, developing the commercialization strategy for EB-101, its autologous, gene-corrected cell therapy for the treatment of recessive dystrophic epidermolysis bullosa and its lead product candidate, as well as leading pre-commercial planning for its investigational adeno-associated virus vector-based gene therapies.

ShowHide Related Items >><<
GILD Gilead
$75.63 /

-0.84 (-1.10%)

ABEO Abeona Therapeutics
$3.42 /

+0.025 (+0.74%)

ABEO Abeona Therapeutics
$3.42 /

+0.025 (+0.74%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
GILD Gilead
$75.63 /

-0.84 (-1.10%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
GILD Gilead
$75.63 /

-0.84 (-1.10%)

ABEO Abeona Therapeutics
$3.42 /

+0.025 (+0.74%)

  • 20
    Dec
GILD Gilead
$75.63 /

-0.84 (-1.10%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

Conference/Events
International Aids Society to hold a virtual conference » 04:55
07/09/20
07/09
04:55
07/09/20
04:55
ABT

Abbott

$92.57 /

+0.21 (+0.23%)

, BDX

Becton Dickinson

$252.65 /

+1.24 (+0.49%)

, GILD

Gilead

$75.63 /

-0.84 (-1.10%)

, HOLX

Hologic

$57.58 /

+0.72 (+1.27%)

, MRK

Merck

$77.87 /

-0.77 (-0.98%)

, OSUR

OraSure

$13.36 /

+0.37 (+2.85%)

23rd International AIDS…

23rd International AIDS Virtual Conference: AIDS 2020 will be held on July 6-10. Webcast Link

ShowHide Related Items >><<
OSUR OraSure
$13.36 /

+0.37 (+2.85%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

HOLX Hologic
$57.58 /

+0.72 (+1.27%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

BDX Becton Dickinson
$252.65 /

+1.24 (+0.49%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

07/01/20 Lake Street
Lake Street says Tandem pact with Abbott, coverage news both 'very positive'
06/15/20 Piper Sandler
Abbott approval narrows competitive gap to DexCom, says Piper Sandler
06/11/20 UBS
Abbott's COVID-19 testing positive contributor, says UBS
06/09/20 Barrington
Surmodics price target raised to $62 from $56 at Barrington
BDX Becton Dickinson
$252.65 /

+1.24 (+0.49%)

04:47 Today Barclays
Becton Dickinson upgraded to Overweight from Equal Weight at Barclays
07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
07/02/20 Wells Fargo
Becton rapid antigen COVID test may be available very soon, says Wells Fargo
06/25/20 Raymond James
Becton Dickinson price target lowered to $265 from $290 at Raymond James
GILD Gilead
$75.63 /

-0.84 (-1.10%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
HOLX Hologic
$57.58 /

+0.72 (+1.27%)

07/02/20 Needham
Hologic price target raised to $64 from $60 at Needham
06/30/20 Cowen
Hologic helped by COVID testing, Cowen upgrades to Outperform
06/30/20 Cowen
Hologic upgraded to Outperform from Market Perform at Cowen
06/16/20 BTIG
Hologic price target raised to $60 from $54 at BTIG
MRK Merck
$77.87 /

-0.77 (-0.98%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
OSUR OraSure
$13.36 /

+0.37 (+2.85%)

06/25/20 Lake Street
OraSure initiated with a Buy at Lake Street
04/21/20 Stephens
OraSure resumed with an Equal Weight at Stephens
OSUR OraSure
$13.36 /

+0.37 (+2.85%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

HOLX Hologic
$57.58 /

+0.72 (+1.27%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

BDX Becton Dickinson
$252.65 /

+1.24 (+0.49%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

  • 03
    Jun
  • 21
    May
MRK Merck
$77.87 /

-0.77 (-0.98%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

OSUR OraSure
$13.36 /

+0.37 (+2.85%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

HOLX Hologic
$57.58 /

+0.72 (+1.27%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

BDX Becton Dickinson
$252.65 /

+1.24 (+0.49%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

MRK Merck
$77.87 /

-0.77 (-0.98%)

HOLX Hologic
$57.58 /

+0.72 (+1.27%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

ABT Abbott
$92.57 /

+0.21 (+0.23%)

Yesterday
On The Fly
Fly Intel: After-Hours Movers » 18:59
07/08/20
07/08
18:59
07/08/20
18:59
EXFO

EXFO Inc.

$3.24 /

+0.1 (+3.18%)

, SAR

Saratoga Investment

$15.61 /

+0.475 (+3.14%)

, ACER

Acer Therapeutics

$3.21 /

+0.07 (+2.23%)

, OPTN

Optinose

$4.26 /

-0.28 (-6.17%)

, ANAB

AnaptysBio

$22.71 /

+0.05 (+0.22%)

, VERI

Veritone

$12.11 /

-0.26 (-2.10%)

, PTC

PTC

$78.36 /

+1.76 (+2.30%)

, SAP

SAP

$146.75 /

+2.75 (+1.91%)

, CRNX

Crinetics

$16.46 /

-0.62 (-3.63%)

, FTCH

Farfetch

$19.59 /

+1.4 (+7.70%)

, COST

Costco

$316.38 /

+0.095 (+0.03%)

, REGN

Regeneron

$639.69 /

-0.92 (-0.14%)

, BBBY

Bed Bath & Beyond

$10.40 /

+0.15 (+1.46%)

, OTIC

Otonomy

$3.58 /

+0.01 (+0.28%)

, GLG

TD Holdings

$2.44 /

+0.06 (+2.52%)

, TPB

Turning Point Brands

$26.50 /

+1.945 (+7.92%)

, FIVE

Five Below

$103.28 /

+4.72 (+4.79%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VERI Veritone
$12.11 /

-0.26 (-2.10%)

TPB Turning Point Brands
$26.50 /

+1.945 (+7.92%)

SAR Saratoga Investment
$15.61 /

+0.475 (+3.14%)

SAP SAP
$146.75 /

+2.75 (+1.91%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

PTC PTC
$78.36 /

+1.76 (+2.30%)

OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

OPTN Optinose
$4.26 /

-0.28 (-6.17%)

GLG TD Holdings
$2.44 /

+0.06 (+2.52%)

FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

FIVE Five Below
$103.28 /

+4.72 (+4.79%)

EXFO EXFO Inc.
$3.24 /

+0.1 (+3.18%)

CRNX Crinetics
$16.46 /

-0.62 (-3.63%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

ANAB AnaptysBio
$22.71 /

+0.05 (+0.22%)

ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

EXFO EXFO Inc.
$3.24 /

+0.1 (+3.18%)

SAR Saratoga Investment
$15.61 /

+0.475 (+3.14%)

01/13/20 Ladenburg
Saratoga Investment upgraded to Buy from Neutral at Ladenburg
01/09/20 Compass Point
Saratoga Investment upgraded to Buy from Neutral at Compass Point
12/19/19 National Securities
Saratoga Investment initiated with a Neutral at National Securities
08/29/19 Aegis
Saratoga Investment initiated with a Buy at Aegis
ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

OPTN Optinose
$4.26 /

-0.28 (-6.17%)

06/30/20 Cantor Fitzgerald
OptiNose anti-COVID-19 candidate could provide 'significant upside, says Cantor
02/07/20 Piper Sandler
Piper Sandler views Optinose risk/reward as attractive after allergist survery
12/18/19 Cowen
Optinose initiated with an Outperform at Cowen
10/01/19 Jefferies
Optinose risk/reward looks increasingly attractive, says Jefferies
ANAB AnaptysBio
$22.71 /

+0.05 (+0.22%)

01/16/20 Cantor Fitzgerald
AnaptysBio risk/reward favorable into second half data, says Cantor Fitzgerald
11/11/19 SunTrust
AnaptysBio downgraded to Hold from Buy at SunTrust
11/08/19 Cantor Fitzgerald
Cantor cuts AnaptysBio target to $28 from $140, sees value in shares
11/08/19 Jefferies
AnaptysBio downgraded to Hold from Buy at Jefferies
VERI Veritone
$12.11 /

-0.26 (-2.10%)

07/06/20 Craig-Hallum
Craig-Hallum says sell Veritone after stock surpasses 'reasonable' valuation
07/06/20 Craig-Hallum
Veritone downgraded to Sell from Hold at Craig-Hallum
06/25/20 Roth Capital
Veritone price target raised to $18 from $7 at Roth Capital
11/08/19 JMP Securities
Veritone price target lowered to $7 from $10 at JMP Securities
PTC PTC
$78.36 /

+1.76 (+2.30%)

06/11/20 Rosenblatt
PTC's highly recurring revenue model underappreciated, says Rosenblatt
06/11/20 Wedbush
PTC price target raised to $78 from $70 at Wedbush
06/10/20 Mizuho
PTC price target raised to $95 from $80 at Mizuho
06/05/20 Needham
PTC initiated with a Buy at Needham
SAP SAP
$146.75 /

+2.75 (+1.91%)

07/08/20 UBS
SAP price target raised to EUR 142 from EUR 118 at UBS
06/16/20 Oppenheimer
SAP price target raised to $137 from $115 at Oppenheimer
06/16/20 RBC Capital
SAP price target raised to $142 from $117 at RBC Capital
06/15/20 Jefferies
SAP price target raised to $149 from $145 at Jefferies
CRNX Crinetics
$16.46 /

-0.62 (-3.63%)

05/11/20 Cantor Fitzgerald
Crinetics price target raised to $38 from $28 at Cantor Fitzgerald
05/08/20 Piper Sandler
Piper Sandler continues to recommend Crinetics after paltusotine data
04/07/20 Piper Sandler
Crinetics shares 'should be up meaningfully,' says Piper Sandler
12/23/19 Roth Capital
Crinetics initiated with a Buy at Roth Capital
FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

07/08/20 China Renaissance
Farfetch upgraded to Buy from Hold at China Renaissance
07/01/20 Deutsche Bank
Farfetch price target raised to $23 from $17 at Deutsche Bank
06/26/20 KeyBanc
Farfetch price target raised to $23 from $17 at KeyBanc
06/25/20 BTIG
Farfetch upgraded to Buy from Neutral at BTIG
COST Costco
$316.38 /

+0.095 (+0.03%)

05/29/20 Baird
Costco improved comps seen likely for May, says Baird
05/29/20 RBC Capital
Costco price target raised to $348 from $332 at RBC Capital
05/06/20 Baird
Costco SSS decline due to pressure from temporal factors, says Baird
04/15/20 Citi
Costco assumed with a Neutral at Citi
REGN Regeneron
$639.69 /

-0.92 (-0.14%)

07/08/20 SunTrust
Regeneron upgraded to Buy at SunTrust on Eylea resilience and pipeline
07/08/20 SunTrust
Regeneron upgraded to Buy from Hold at SunTrust
07/08/20 Canaccord
Regeneron price target raised to $700 from $660 at Canaccord
07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

07/07/20 Raymond James
Bed Bath & Beyond price target raised to $13 from $9 at Raymond James
05/26/20 Odeon Capital
Bed Bath & Beyond upgraded to Buy from Hold at Odeon Capital
04/16/20 Loop Capital
Bed Bath & Beyond Q4 results 'less bad than feared' says Loop Capital
04/08/20 Loop Capital
Bed Bath & Beyond price target lowered to $5 from $12 at Loop Capital
OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

07/07/20 Cantor Fitzgerald
Otonomy price target raised to $11 from $9 at Cantor Fitzgerald
07/07/20 H.C. Wainwright
Otonomy price target raised to $9 from $8 at H.C. Wainwright
06/15/20 Piper Sandler
Piper remains optimistic on Otonomy ahead of near-term clinical readouts
06/01/20 Oppenheimer
Otonomy assumed with an Outperform at Oppenheimer
GLG TD Holdings
$2.44 /

+0.06 (+2.52%)

TPB Turning Point Brands
$26.50 /

+1.945 (+7.92%)

07/08/20 Craig-Hallum
Turning Point Brands initiated with a Buy at Craig-Hallum
01/06/20 Buckingham
Vape plan looks better than expected for Turning Point, says Buckingham
11/26/19 Buckingham
Buckingham starts Turning Point at Buy, says 'far more than a vaping play'
11/26/19 Buckingham
Turning Point Brands initiated with a Buy at Buckingham
FIVE Five Below
$103.28 /

+4.72 (+4.79%)

06/10/20
Fly Intel: Top five analyst upgrades
06/10/20 JPMorgan
Five Below price target raised to $123 from $103 at JPMorgan
06/10/20 Jefferies
Five Below price target raised to $140 from $89 at Jefferies
06/10/20 Credit Suisse
Five Below price target raised to $116 from $93 at Credit Suisse
VERI Veritone
$12.11 /

-0.26 (-2.10%)

TPB Turning Point Brands
$26.50 /

+1.945 (+7.92%)

SAR Saratoga Investment
$15.61 /

+0.475 (+3.14%)

SAP SAP
$146.75 /

+2.75 (+1.91%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

PTC PTC
$78.36 /

+1.76 (+2.30%)

OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

OPTN Optinose
$4.26 /

-0.28 (-6.17%)

FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

FIVE Five Below
$103.28 /

+4.72 (+4.79%)

EXFO EXFO Inc.
$3.24 /

+0.1 (+3.18%)

CRNX Crinetics
$16.46 /

-0.62 (-3.63%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

ANAB AnaptysBio
$22.71 /

+0.05 (+0.22%)

ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

  • 09
    Jul
  • 09
    Jul
  • 27
    May
  • 15
    Apr
  • 21
    Nov
SAP SAP
$146.75 /

+2.75 (+1.91%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

SAR Saratoga Investment
$15.61 /

+0.475 (+3.14%)

SAP SAP
$146.75 /

+2.75 (+1.91%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

FIVE Five Below
$103.28 /

+4.72 (+4.79%)

EXFO EXFO Inc.
$3.24 /

+0.1 (+3.18%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

FIVE Five Below
$103.28 /

+4.72 (+4.79%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

Upgrade
Regeneron upgraded to Buy at SunTrust on Eylea resilience and pipeline » 17:11
07/08/20
07/08
17:11
07/08/20
17:11
REGN

Regeneron

$639.69 /

-0.92 (-0.14%)

SunTrust analyst Robyn…

SunTrust analyst Robyn Karnauskas upgraded Regeneron to Buy from Hold with a price target of $750, up from $400. The analyst is citing her "deep dive" analysis in the company's pipeline and conversations with its management in modeling additional revenue build with credit to its Libtayo, Dupi, fasinumab and oncology pipeline products. Karnauskas adds that Regeneron's base business has demonstrated strength during the COVID environment with resilience of Eylea, stating that she had been "very conservative and modeled significant pricing pressure and loss of share from Beovu and biosimilars".

ShowHide Related Items >><<
REGN Regeneron
$639.69 /

-0.92 (-0.14%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

07/08/20 SunTrust
Regeneron upgraded to Buy from Hold at SunTrust
07/08/20 Canaccord
Regeneron price target raised to $700 from $660 at Canaccord
07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
REGN Regeneron
$639.69 /

-0.92 (-0.14%)

  • 27
    May
REGN Regeneron
$639.69 /

-0.92 (-0.14%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

Hot Stocks
Biogen says 'positive' toferson study results published in NEJM » 17:02
07/08/20
07/08
17:02
07/08/20
17:02
BIIB

Biogen

$280.19 /

+12.01 (+4.48%)

Biogen announced that…

Biogen announced that positive results from a Phase 1/2 study of tofersen for the potential treatment of superoxide dismutase 1 amyotrophic lateral sclerosis were published in The New England Journal of Medicine. A mutation in the SOD1 gene is believed to be a genetic driver of disease in approximately two percent of all ALS cases. "By evaluating genetically validated targets such as SOD1 in defined populations, we believe we can more quickly identify how to treat this devastating disease," said Toby Ferguson, M.D., Ph.D., Vice President and Head of the Neuromuscular Development Unit at Biogen. "Biogen is committed to furthering ALS research in an effort to potentially bring a therapy to people living with this rapidly progressing neurological condition."

ShowHide Related Items >><<
BIIB Biogen
$280.19 /

+12.01 (+4.48%)

BIIB Biogen
$280.19 /

+12.01 (+4.48%)

07/08/20 Credit Suisse
Biogen submits Aducanumab BLA, upside possible near-term, says Credit Suisse
07/08/20 Stifel
Biogen submission of Aducanumab BLA 'an incremental positive,' says Stifel
07/08/20 Goldman Sachs
Goldman says Biogen BLA submission for Alzheimer's drug an incremental positive
07/08/20 Jefferies
Biogen likely to get Priority Review for aducanumab, says Jefferies
BIIB Biogen
$280.19 /

+12.01 (+4.48%)

BIIB Biogen
$280.19 /

+12.01 (+4.48%)

BIIB Biogen
$280.19 /

+12.01 (+4.48%)

BIIB Biogen
$280.19 /

+12.01 (+4.48%)

Upgrade
Regeneron upgraded to Buy from Hold at SunTrust » 16:56
07/08/20
07/08
16:56
07/08/20
16:56
REGN

Regeneron

$639.69 /

-0.92 (-0.14%)

SunTrust analyst Robyn…

SunTrust analyst Robyn Karnauskas upgraded Regeneron Pharmaceuticals to Buy from Hold with a $750 price target.

ShowHide Related Items >><<
REGN Regeneron
$639.69 /

-0.92 (-0.14%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

07/08/20 Canaccord
Regeneron price target raised to $700 from $660 at Canaccord
07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
REGN Regeneron
$639.69 /

-0.92 (-0.14%)

  • 27
    May
REGN Regeneron
$639.69 /

-0.92 (-0.14%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

On The Fly
Fly Intel: Wall Street's top stories for Wednesday » 16:18
07/08/20
07/08
16:18
07/08/20
16:18
LEVI

Levi Strauss

$12.68 /

-1.195 (-8.62%)

, FB

Facebook

$243.58 /

+2.51 (+1.04%)

, BIIB

Biogen

$280.15 /

+11.97 (+4.46%)

, ALL

Allstate

$88.20 /

-4.38 (-4.73%)

, NGHC

National General

$33.73 /

+13.29 (+65.02%)

, TWTR

Twitter

$35.39 /

+2.41 (+7.31%)

, MRNA

Moderna

$61.58 /

+0.5 (+0.82%)

, GM

General Motors

$24.93 /

-0.19 (-0.76%)

, FCAU

Fiat Chrysler

$9.99 /

-0.09 (-0.89%)

, XENT

Intersect ENT

$17.98 /

+4.07 (+29.26%)

, MDT

Medtronic

$91.64 /

-0.05 (-0.05%)

, NKLA

Nikola

$54.03 /

+13.78 (+34.24%)

, GILT

Gilat Satellite

$5.20 /

-0.905 (-14.82%)

, CMTL

Comtech

$15.87 /

+0.32 (+2.06%)

Stocks continue to rise…

Open Full Text

ShowHide Related Items >><<
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

NGHC National General
$33.73 /

+13.29 (+65.02%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

06/16/20 Exane BNP Paribas
Levi Strauss initiated with an Outperform at Exane BNP Paribas
04/09/20 Guggenheim
Levi Strauss price target lowered to $16 from $26 at Guggenheim
04/08/20 Citi
Levi Strauss has ample liquidity and remains 'strong brand,' says Citi
03/18/20 BofA
Levi Strauss downgraded to Neutral with $15 price target at BofA
FB Facebook
$243.58 /

+2.51 (+1.04%)

08:15 Today Wedbush
Pinterest price target raised to $31 from $26 at Wedbush
07/07/20 BofA
Potential U.S. ban of TikTok could be tailwind to Snap engagement, says BofA
07/01/20 Monness Crespi
Facebook has opportunity to emerge from crisis stronger, says Monness Crespi
07/01/20 Goldman Sachs
Facebook checks show limited impact from ad boycott, says Goldman Sachs
BIIB Biogen
$280.15 /

+11.97 (+4.46%)

07/08/20 Credit Suisse
Biogen submits Aducanumab BLA, upside possible near-term, says Credit Suisse
07/08/20 Stifel
Biogen submission of Aducanumab BLA 'an incremental positive,' says Stifel
07/08/20 Goldman Sachs
Goldman says Biogen BLA submission for Alzheimer's drug an incremental positive
07/08/20 Jefferies
Biogen likely to get Priority Review for aducanumab, says Jefferies
ALL Allstate
$88.20 /

-4.38 (-4.73%)

08:37 Today B. Riley FBR
National General downgraded to Neutral from Buy at B. Riley FBR
06:49 Today Citi
Allstate acquisition of National an incremental positive, says Citi
06:20 Today JMP Securities
National General downgraded to Market Perform from Outperform at JMP Securities
07/08/20 William Blair
National General downgraded to Market Perform from Outperform at William Blair
NGHC National General
$33.73 /

+13.29 (+65.02%)

06:16 Today B. Riley FBR
National General downgraded to Neutral from Buy at B. Riley FBR
TWTR Twitter
$35.39 /

+2.41 (+7.31%)

07:01 Today Citi
Twitter shares overreacted to paid service potential, says Citi
07/08/20 Rosenblatt
Rosenblatt says 'highly unlikely' Twitter considering paid subscription tiers
06/30/20 Morgan Stanley
Morgan Stanley says buy Facebook amid boycott-driven weakness
06/29/20 Stifel
Stifel says Facebook sales won't be materially hurt unless ad boycott broadens
MRNA Moderna
$61.58 /

+0.5 (+0.82%)

07/08/20 Piper Sandler
Piper reiterates $100 target on Moderna after Phase II study enrolled
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
06/30/20 Argus
Moderna initiated with a Buy at Argus
06/30/20 Argus
Moderna initiated with a Buy at Argus
GM General Motors
$24.93 /

-0.19 (-0.76%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
General Motors price target raised to $33 from $29 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

06/30/20 UBS
Fiat Chrysler price target raised to EUR 9 from EUR 6 at UBS
06/22/20 Redburn
Fiat Chrysler upgraded to Buy from Neutral at Redburn
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

07/08/20 Oppenheimer
Takeout bid of $17 for Intersect ENT would be 'reasonable,' says Oppenheimer
06/23/20 Oppenheimer
Intersect ENT initiated with a Perform at Oppenheimer
06/09/20 SVB Leerink
Intersect ENT C-code issuance has 'mixed implications,' says SVB Leerink
06/09/20 Piper Sandler
Intersect ENT's C-Code approval adds access to 40M lives, says Piper Sandler
MDT Medtronic
$91.64 /

-0.05 (-0.05%)

06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
06/30/20 Piper Sandler
United Health coverage a 'clear positive' for Tandem, says Piper Sandler
06/18/20 Argus
Medtronic has strong growth opportunities, says Argus
NKLA Nikola
$54.03 /

+13.78 (+34.24%)

07/08/20
Fly Intel: Top five analyst upgrades
07/08/20 JPMorgan
JPMorgan upgrades Nikola to Overweight after 40% July selloff
07/08/20 JPMorgan
Nikola upgraded to Overweight from Neutral at JPMorgan
07/07/20 RBC Capital
Nikola initiated with a Sector Perform at RBC Capital
GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

06/04/20 Northland
Comtech price target lowered to $24 from $27 at Northland
03/31/20 Citi
Comtech price target lowered to $17 from $34 at Citi
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NGHC National General
$33.73 /

+13.29 (+65.02%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

  • 19
    May
  • 12
    Feb
XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

GILT Gilat Satellite
$5.20 /

-0.905 (-14.82%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

XENT Intersect ENT
$17.98 /

+4.07 (+29.26%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

CMTL Comtech
$15.87 /

+0.32 (+2.06%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

ALL Allstate
$88.20 /

-4.38 (-4.73%)

TWTR Twitter
$35.39 /

+2.41 (+7.31%)

NKLA Nikola
$54.03 /

+13.78 (+34.24%)

MRNA Moderna
$61.58 /

+0.5 (+0.82%)

MDT Medtronic
$91.64 /

-0.05 (-0.05%)

LEVI Levi Strauss
$12.68 /

-1.195 (-8.62%)

GM General Motors
$24.93 /

-0.19 (-0.76%)

FCAU Fiat Chrysler
$9.99 /

-0.09 (-0.89%)

FB Facebook
$243.58 /

+2.51 (+1.04%)

BIIB Biogen
$280.15 /

+11.97 (+4.46%)

Hot Stocks
Gilead starts Phase 1a trial of inhaled remdesivir in healthy volunteers » 14:31
07/08/20
07/08
14:31
07/08/20
14:31
GILD

Gilead

$75.11 /

-1.36 (-1.78%)

Gilead Sciences a…

Gilead Sciences a statement from Merdad Parsey, its Chief Medical Officer: "Since the beginning of the COVID-19 pandemic, Gilead has mobilized its deep expertise in virology to rapidly assess the potent investigational antiviral, remdesivir, to evaluate its safety and efficacy as a potential treatment option for patients with COVID-19. With promising data emerging from the randomized, clinical trials of intravenous remdesivir administered to hospitalized patients, it became clear that efforts were needed to investigate the drug's potential in the outpatient setting. Significant research efforts have been undertaken to deliver remdesivir in an inhaled, nebulized format. We are pleased to announce the initiation of a Phase 1a clinical study to evaluate the safety, tolerability and pharmacokinetics of an investigational, inhaled solution of remdesivir in healthy volunteers. Based on current scientific understanding, the upper respiratory tract is the most prevalent site of SARS-CoV-2 infection early in disease. Delivering remdesivir directly to the primary site of infection with a nebulized, inhaled solution may enable more targeted and accessible administration in non-hospitalized patients and potentially lower systemic exposure to the drug. This randomized, placebo-controlled trial will enroll approximately 60 healthy individuals aged 18-45 in the United States to form the basis for further clinical study of the inhaled drug, particularly in patients whose disease has not progressed to require hospitalization."

ShowHide Related Items >><<
GILD Gilead
$75.11 /

-1.36 (-1.78%)

GILD Gilead
$75.11 /

-1.36 (-1.78%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
GILD Gilead
$75.11 /

-1.36 (-1.78%)

GILD Gilead
$75.11 /

-1.36 (-1.78%)

GILD Gilead
$75.11 /

-1.36 (-1.78%)

GILD Gilead
$75.11 /

-1.36 (-1.78%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.